In Vivo evaluation of silybin nanosuspensions targeting liver

Journal of Biomedical Nanotechnology

Volumn 8, Issue 5, 2012, Pages 760-769

  Wang, Yancai ^a   Wang, Lianqin ^b   Liu, Zhaoping ^c   Zhang, Dianrui ^c   Zhang, Qiang ^d  

^a SHANDONG POLYTECHNIC UNIVERSITY   (China)

^b Hospital of Shandong Polytechnic University   (China)

^c SHANDONG UNIVERSITY   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Biodistribution; Nanosuspensions; Pharmacodynamics; Silybin; Targeting delivery

Indexed keywords

AFM; BEAGLE DOG; BIODISTRIBUTIONS; CONTROL GROUPS; DRUG TARGETS; HEPATOPROTECTIVE; IN-VIVO; INTRAVENOUS ADMINISTRATION; KINETIC STUDY; LARGER PARTICLE SIZES; NANO-SUSPENSIONS; PHYSICOCHEMICAL PROPERTY; SERUM MARKERS; SILYBIN; SMALL PARTICLES; TARGETING DELIVERY; THERAPEUTIC EFFICACY;

ENZYME INHIBITION; PHARMACODYNAMICS;

PARTICLE SIZE;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; SILIBININ;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATOMIC FORCE MICROSCOPY; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG NANOSUSPENSION; DRUG STRUCTURE; EVALUATION; EXPERIMENTAL DOG; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; LIVER; LIVER PROTECTION; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SPLEEN; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTIOXIDANTS; CARBON TETRACHLORIDE POISONING; DOGS; DRUG COMPOUNDING; DRUG-INDUCED LIVER INJURY, CHRONIC; METABOLIC CLEARANCE RATE; MICE; NANOCAPSULES; ORGAN SPECIFICITY; SILYMARIN; SUSPENSIONS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84865112011     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1444     Document Type: Article

References (33)

1. 4-induced liver damage. Biochem. Biophys. Res. Commun. 329, 991 (2005).
2. A. Valenzuela and R. Guerra, Protective effect of the flavonoid silybin dihemisuccinate on the toxicity of phenylhydrazine on rat liver. FEBS. Lett. 181, 291 (1985).
3. R. P. Singh, K. Raina, G. Deep, D. Chan, and R. Agarwal, Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin. Cancer. Res. 15, 613 (2009).
4. T. W. Flaig, D. L. Gustafson, L. J. Su, J. A. Zirrolli, F. Crighton, and G. S. Harrison, A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest. New Drugs. 25, 139 (2007).
5. A. R. Bartholomaeus, R. Bolton, and J. T. Ahokas, Inhibition of rat liver cytosolic glutathione S-transferase by silybin. Xenobiotica. 24, 17 (1994).
6. H. Koch and J. Tscherny, Bioavailability of silymarin, 3: Splitting of silybin dihemisuccinate by plasma and liver esterases. Arch. Pharm. 316, 426 (1983).
7. Y. Wang, D. Zhang, Z. Liu, G. Liu, C. Duan, and L. Jia, In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 21, 155104 (2010).
8. B. E. Rabinow, Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785 (2004).
9. M. Sun, Y. Gao, Y. Pei, C. Guo, H. Li, and F. Cao, Development of nanosuspension formulation for oral delivery of quercetin. J. Biomed. Nanotechnol. 6, 325 (2010).
10. B. Van Eerdenbrugh, J. Vermant, J. A. Martens, L. Froyen, J. Van Humbeeck, and P. Augustijns, A screening study of surface stabilization during the production of drug nanocrystals. J. Pharm. Sci. 98, 2091 (2009).
11. J. Deng, L. Huang, and F. Liu, Extraction issues of paclitaxel in nanocrystals. J. Biomed. Nanotechnol. 6, 198 (2010).
12. C. Jacobs and R. H. Muller, Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19, 189 (2002).
13. R. Mauludin, R. H. Muller, and C. M. Keck, Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur. J. Pharm. Sci. 36, 502 (2009).
14. J. Moschwitzer and R. H. Muller, Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur. J. Pharm. Biopharm. 62, 282 (2006).
15. R. H. Muller, C. Jacobs, and O. Kayser, Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3 (2001).
16. G. H. Wolfgang, R. A. Jolly, W. J. Donarski, and R. Ochoa, T. W, Petry, Inhibition of carbon tetrachloride-induced lipid peroxidation by novel antioxidants in rat hepatic microsomes: Dissociation from hepatoprotective effects in vivo. J. Biochem. Toxicol. 5, 167 (1990).
17. I. Friedrich and C. C. Muller-Goymann, Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS-based nanosuspensions. Eur. J. Pharm. Biopharm. 56, 111 (2003).
18. J. Moschwitzer, G. Achleitner, H. Pomper, and R. H. Muller, Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 58, 615 (2004).
19. H. Epstein, V. Berger, I. Levi, G. Eisenberg, N. Koroukhov, and J. C. Gao, Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J. Control. Release. 117, 322 (2007).
20. H. M. Patel and S. M. Moghimi, Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. Adv. Drug Deliv. Rev. 32, 45 (1998).
21. R. H. Muller and C. Jacobs, Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int. J. Pharm. 237, 151 (2002).
22. B. Van Eerdenbrugh, L. Froyen, J. Van Humbeeck, J. A. Martens, P. Augustijns, and G. Van Den Mooter, Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. Eur. J.Pharm. Sci. 35, 344 (2008).
23. W. H. De Jong, W. I. Hagens, P. Krystek, M. C. Burger, A. J. Sips, and R. E. Geertsma, Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 29, 1912 (2008).
24. B. Semete, L. Booysen, Y. Lemmer, L. Kalombo, L. Katata, and J. Verschoor, In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 6, 662 (2010).
25. L. Gao, D. R. Zhang, M. H. Chen, C. X. Duan, W. T. Dai, and L. J. Jia, Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 355, 321 (2008).
26. J. Wong, A. Brugger, A. Khare, M. Chaubal, P. Papadopoulos, and B. Rabinow, Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 60, 939 (2008).
27. R. H. Muller and C. M. Keck, Challenges and solutions for the delivery of biotech drugs - A review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113, 151 (2004).
28. 4induced hepatic damage in rats. J. Ethnopharmacol. 127, 777 (2010).
29. K. Manjunath and V. Venkateswarlu, Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release. 107, 215 (2005).
30. 4-induced oxidative damage in rats. Food. Chem. Toxicol. 46, 3182 (2008).
31. 4-induced liver damage. Food. Chem. Toxicol. 42, 609 (2004).
32. 4-induced toxicity in rats. Exp. Toxicol. Pathol. 63, 363 (2011).
33. 4-induced acute hepatic injury in experimental rats. J. Ethnopharmacol. 105, 154 (2006).